Reuters logo
BRIEF-U.S. FDA Division of Hematology products lifts partial clinical hold on Selinexor clinical trials
March 30, 2017 / 11:22 AM / 6 months ago

BRIEF-U.S. FDA Division of Hematology products lifts partial clinical hold on Selinexor clinical trials

March 30 (Reuters) - Karyopharm Therapeutics Inc

* U.S. FDA Division of Hematology products lifts partial clinical hold on Karyopharm’S Selinexor clinical trials

* Timelines for ongoing and planned studies expected to remain materially unchanged

* Recruitment resumes across all Selinexor trials in hematological malignancies

* Investigator sponsored trials in hematologic malignancies with Selinexor may resume accruing patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below